Compound Reference
Selank Research Overview
Last updated:
Selank is a synthetic analog of tuftsin, a naturally occurring immunomodulatory peptide.
Selank has no approved human medical indication and has not been evaluated by the FDA or any other regulatory body for safety or efficacy in humans. Published research on Selank is overwhelmingly preclinical: conducted in vitro (cell and tissue culture) or in animal models, primarily rodents. We are not aware of well-controlled human clinical trials establishing a therapeutic effect for any condition.
Published research on selank, also largely originating from Russian pharmacological literature, is concentrated in behavioral and immunological models:
- Anxiolytic-like behavioral research — rodent behavioral models have been used to study selank in the context of anxiety-related endpoints.
- Immunomodulatory research — as a tuftsin analog, selank has been studied for its association with immune-signaling pathways.
- Monoamine and GABA-system research — animal studies have investigated selank's association with GABA- and monoamine-related neurotransmitter systems.
These are summaries of published research topics, not claims about what this product does, and animal-model findings do not establish an effect in humans. See References below to search the primary literature directly.
Limitations
State of the Evidence
Selank's published literature, like semax's, is concentrated in a specific national research tradition with limited independent replication elsewhere; rodent behavioral and immunological findings do not establish an equivalent effect in humans.
References
Primary Literature
The links below open a PubMed search for each research topic referenced above, rather than a single citation, so you can review the primary literature directly rather than rely on our summary of it.
All products are intended for laboratory and research purposes only. Not for human or veterinary use. Not a drug. Not for diagnostic or therapeutic use.